Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Sunahara, R. K., Guan, H.-C., O'Dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Van Tol, H. H. M., & Niznik, H. B. (1991) · Nature · doi:10.1038/350614a0 · Cited by 1,165
The physiology of brain histamine
Brown, R. E., Stevens, D. R., & Haas, H. L. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00039-3 · Cited by 988
Principles of Multivariate Analysis
Ling, R. F. (1990) · Technometrics · doi:10.1080/00401706.1990.10484645 · Cited by 812
Distinct functions of the two isoforms of dopamine D2 receptors
Usiello, A., Baik, J.-H., Rougé-Pont, F., Picetti, R., Dierich, A., LeMeur, M., Piazza, P. V., & Borrelli, E. (2000) · Nature · doi:10.1038/35041572 · Cited by 717 · cited 2×
“…release and may contribute to neuroprotective properties of antiparkinson agents; and 3) postsynaptic D 2S and (predominant) hD 2L sites, perhaps via contrasting interactions with D 1 receptors, differentially control motor function (Zou et al., 1999; Usiello et al., 2000). hD 3 and hD 4 Receptors.”
BackgroundInteractions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence
Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.237 · Cited by 688
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086062 · Cited by 503
Meneses, A. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00067-6 · Cited by 475
Principles of Multivariate Analysis: A User’s Perspective
Krzanowski, W. J. (2000) · doi:10.1093/oso/9780198507086.001.0001 · Cited by 467
The dopamine D4 receptor: one decade of research
Oak, J. N., Oldenhof, J., & Van Tol, H. H. M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00562-8 · Cited by 419
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Self-citationGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Self-citationMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease
Voon, V., & Fox, S. H. (2007) · Archives of Neurology · doi:10.1001/archneur.64.8.1089 · Cited by 397
Ruxton, K., Woodman, R. J., & Mangoni, A. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12617 · Cited by 360
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“6), and acts as an agonist at a variety of serotonergic, dopaminergic, and adrenergic receptors (Leysen, 1989; Piercey et al,. 1996; Egan et al., 1998; Marona-Lewicka et al., 2002; Millan et al., 2002; Nichols et al., 2002).”
BackgroundA review of the receptor-binding and pharmacokinetic properties of dopamine agonists
Kvernmo, T., Härtter, S., & Burger, E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.004 · Cited by 277
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease
Saraiva, C., Paiva, J., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.005 · Cited by 169
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
Metadata
- Authors
- Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.-A., & Newman-Tancredi, A.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 303
- Issue
- 2
- Pages
- 791-804
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2168954492
- Cited by
- 484
- References
- 51
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.